{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T09:48:55Z","timestamp":1792144135942,"version":"4.4.0"},"reference-count":0,"publisher":"Armed Forces Medical Services","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Saudi Medical Journal"],"abstract":"<jats:p>Diffuse large B-cell lymphoma (DLBCL), the most prevalent aggressive non-Hodgkin lymphoma, exhibits substantial molecular heterogeneity and arises from germinal center or post-germinal center B cells through recurrent genetic and epigenetic dysregulation of critical signaling pathways. Aberrations involving BCL6, MYC, MYD88, and components of B cell receptor and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-\u03ba B) signaling play central roles in lymphomagenesis, treatment resistance, and clinical outcomes. Gene expression profiling has defined major molecular subgroups in DLBCL, including germinal center B cell\u2013like and activated B cell\u2013like tumors, that show distinct pathogenesis and prognosis. High-risk entities, such as double- and triple-hit lymphomas, remain therapeutically challenging despite advances in immunochemotherapy. Recent progress in molecular diagnostics and targeted therapies, including immune checkpoint inhibition, Bruton tyrosine kinase inhibitors, B-cell lymphoma 2 (BCL2) antagonists, and Chimeric antigen receptor-T cells, has expanded precision-based treatment strategies. This review summarizes advances in understanding the molecular mechanisms of DLBCL and emphasizes emerging therapeutic approaches informed by genomic and microenvironmental discoveries.<\/jats:p>","DOI":"10.15537\/1658-3175.8802","type":"journal-article","created":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T16:41:00Z","timestamp":1781455260000},"page":"1141-1149","source":"Crossref","is-referenced-by-count":0,"title":["Molecular Mechanisms of Diffuse Large B-Cell Lymphoma and the Complexities of Tumor Development"],"prefix":"10.15537","volume":"47","author":[{"given":"Wael I.","family":"Alzahrani","sequence":"first","affiliation":[{"name":"Department of Clinical Laboratory Science, College of Applied Medical Sciences-Qurayyat, Jouf University, Al Jouf, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56029","published-online":{"date-parts":[[2026,6,9]]},"container-title":["Saudi Medical Journal"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T09:26:44Z","timestamp":1792142804000},"score":1,"resource":{"primary":{"URL":"https:\/\/smj.researchcommons.org\/journal\/vol47\/iss7\/5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,9]]},"references-count":0,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,6,9]]}},"URL":"https:\/\/doi.org\/10.15537\/1658-3175.8802","relation":{},"ISSN":["1658-3175"],"issn-type":[{"value":"1658-3175","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,9]]}}}